LYPHF Stock Chart & Stats
$0.27
-$0.05(-14.80%)
At close: 4:00 PM EDT
$0.27
-$0.05(-14.80%)
Day’s Range― - ―
52-Week Range$0.20 - $0.41
Previous CloseN/A
Volume2.50K
Average Volume (3M)0.00
Market Cap
$916.46M
Enterprise Value$8.58K
Total Cash (Recent Filing)$8.88B
Total Debt (Recent Filing)$9.42B
Price to Earnings (P/E)8.9
Beta-0.16
Next Earnings
Mar 31, 2027EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend Yield2.17%
Share Statistics
EPS (TTM)0.16
Shares Outstanding3,994,515,900
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.67
Price to Book (P/B)0.60
Price to Sales (P/S)1.52
P/FCF Ratio12.29
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$0.34Price Target Upside26.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.02
Revenue Forecast (FY)$782.65M
Bulls Say, Bears Say
Bulls Say
Strong ProfitabilityHigh gross and operating margins indicate that Luye Pharma retains meaningful economics in its branded and specialty medicines. This profitability provides capacity to fund research, commercialization, and product life-cycle initiatives while supporting resilience against operating pressures over the coming quarters.
Improving LeverageLower leverage and a larger equity base strengthen financial flexibility relative to earlier years. A more conservative balance sheet can reduce financing pressure, support continued investment in the pipeline, and improve the company’s ability to manage volatility in pharmaceutical revenues.
Operating Cash Flow ReboundThe return to positive operating and free cash flow demonstrates that the business generated cash after the prior year’s shortfall. This improves internal funding capacity for development, manufacturing, and commercialization, although the broader record remains uneven across years.
Bears Say
Sharp Revenue ContractionThe steep revenue decline raises concern about the durability of demand and the stability of the current profit base. Even with strong margins, sustained contraction could reduce operating leverage, limit reinvestment capacity, and make future earnings more dependent on successful new products.
Volatile Free Cash FlowRepeated swings in free cash flow make cash returns less predictable than reported profitability. Moderate conversion in 2025 also suggests that earnings do not consistently translate into deployable cash, potentially constraining reliable investment, debt reduction, and shareholder distributions.
Low Return On EquityLow return on equity indicates that the enlarged capital base is producing limited bottom-line efficiency. Unless profitability improves relative to equity, this may constrain value creation from retained capital and signal that strong operating margins are not fully translating into shareholder returns.
Luye Pharma Group News
LYPHF FAQ
What was Luye Pharma Group Ltd.’s price range in the past 12 months?
Luye Pharma Group Ltd. lowest stock price was $0.20 and its highest was $0.41 in the past 12 months.
What is Luye Pharma Group Ltd.’s market cap?
Luye Pharma Group Ltd.’s market cap is $916.46M.
When is Luye Pharma Group Ltd.’s upcoming earnings report date?
Luye Pharma Group Ltd.’s upcoming earnings report date is Mar 31, 2027 which is in 200 days.
How were Luye Pharma Group Ltd.’s earnings last quarter?
Luye Pharma Group Ltd. released its earnings results on Aug 30, 2026. The company reported $0.004 earnings per share for the quarter, missing the consensus estimate of $0.007 by -$0.004.
Is Luye Pharma Group Ltd. overvalued?
According to Wall Street analysts Luye Pharma Group Ltd.’s price is currently Undervalued.
Does Luye Pharma Group Ltd. pay dividends?
Luye Pharma Group Ltd. pays a Annually dividend of $0.008 which represents an annual dividend yield of 2.17%. See more information on Luye Pharma Group Ltd. dividends here
What is Luye Pharma Group Ltd.’s EPS estimate?
Luye Pharma Group Ltd.’s EPS estimate is <0.01.
How many shares outstanding does Luye Pharma Group Ltd. have?
Luye Pharma Group Ltd. has 3,994,515,900 shares outstanding.
What happened to Luye Pharma Group Ltd.’s price movement after its last earnings report?
Luye Pharma Group Ltd. reported an EPS of $0.004 in its last earnings report, missing expectations of $0.007. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Luye Pharma Group Ltd.?
Currently, no hedge funds are holding shares in LYPHF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Luye Pharma Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$0.34 (26.43% Upside)
$0.34 (26.43% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
0.74%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
14.98%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Luye Pharma Group Ltd.
Luye Pharma Group Ltd. functions as a global investment holding enterprise, focusing on the worldwide development, production, marketing, and sales of pharmaceutical products. The company's diverse portfolio includes several key oncology treatments: Lipusu for ovarian and breast cancers; CMNa, a chemical sensitizer used in cancer radiotherapy; Tiandida, targeting ovarian or non-small cell lung cancer; and Boyounuo, an injectable medication for various cancers and solid tumors. It also offers Yitaida for acute promyelocytic leukemia and liver cancer, and Lutingnuo, a glutathione injection for combating toxicity and injuries from ionizing radiation. Tiandixin serves as an adjuvant therapy for malignant tumors, hydrothorax, ascites, and respiratory infections. In the metabolic and cardiovascular health sector, Luye Pharma provides Xuezhikang, a lipid-regulating drug for hypercholesterolemia; Beitangning, a pioglitazone hydrochloride capsule for blood glucose control; and Beixi, an acarbose capsule for Type 2 diabetes. For neurological conditions and pain management, offerings include Maitongna, indicated for cerebral edema caused by trauma or surgery, and for venous reflux disorders. Transdermal patches such as Rivastigmine are available for Alzheimer's disease, Fentanyl for cancer pain, and Buprenorphine for chronic pain relief. Additionally, Seroquel and Seroquel XR are provided for treating schizophrenia and manic episodes associated with bipolar affective disorders. Rykindo, an injection for schizophrenia, is also part of their neurological therapeutics. Further therapeutic solutions span various conditions: Nuosen for acute upper digestive tract hemorrhage; Sailimai for diarrhea treatment; and the Apleek Transdermal Patch for contraception. Addressing musculoskeletal and inflammatory issues, the company offers Sidinuo for osteoporosis, Glucosamine hydrochloride tablets for osteoarthritis, Oulai (a compound sodium aescinate gel) for localized swelling, Oukai for soft tissue swelling and venous edema, and Fengshiye for pain in bones, joints, and limbs. Beyond product development, Luye Pharma Group actively engages in the distribution and commercialization of its pharmaceutical drugs, along with the manufacturing and sale of biopharmaceutical products. The company was established in 1994 and is headquartered in Yantai, People's Republic of China.
LYPHF Stock 12 Month Forecast
Average Price Target
$0.34
▲(26.43% Upside)
Technical Analysis
CSPC Pharmaceutical Group
―
Zai Lab Ltd
―
Consun Pharmaceutical Group Ltd.
―
Lepu Biopharma Co. Ltd. Class H
―
CStone Pharmaceuticals
―
Ownership Overview
―
Insiders
2.44% Mutual Funds
― Other Institutional Investors
94.71% Public Companies and
Individual Investors